Tiziana Life Sciences Ltd (TLSA)

USD 0.99

(0.02%)

Market Cap (In USD)

109.55 Million

Revenue (In USD)

-

Net Income (In USD)

-16.2 Million

Avg. Volume

259.61 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
0.41-1.74
PE
-
EPS
-
Beta Value
0.178
ISIN
BMG889121031
CUSIP
88875G101
CIK
1723069
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Gabriele Marco Antonio Cerrone M.B.A.
Employee Count
-
Website
https://www.tizianalifesciences.com
Ipo Date
2018-11-20
Details
Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti-Interleukin 6 receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation and to treat COVID-19 patients. The company was incorporated in 1998 and is headquatered in London, the United Kingdom.